NV-MOVELLA
16.7.2024 16:01:31 CEST | Business Wire | Press release
Movella, a leading provider of full-stack solutions for digitizing movement, today announced it has enhanced its Xsens MTi™ inertial sensor modules for autonomous machines and edge AI applications. The Xsens MTi sensors can be easily integrated with the NVIDIA Jetson™ platform for edge AI and robotics, offering full compatibility with the NVIDIA Jetson AGX Orin™, NVIDIA Jetson Orin™ NX, and NVIDIA Jetson Orin Nano™ system-on-modules.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716567003/en/
(Graphic: Business Wire)
The highly compact Xsens MTi sensors, also called “IMU”, are renowned for their high accuracy, reliability, and low latency, even under adverse conditions. They provide industrial-grade, real-time measurements of motion, orientation, and global position (GNSS), which are critical for navigating and controlling a wide range of mobile robots and smart automation applications, whether aerial, land-based, or subsea. Offering compatibility with the powerful AI capabilities of the NVIDIA Jetson platform, the Xsens MTi inertial sensors will help customers bring their intelligent and autonomous systems faster to the market.
The easy integration of NVIDIA Jetson Orin modules with Xsens MTi sensors will help enable more intelligent and efficient autonomous systems. Movella is a member of the NVIDIA Partner Network (NPN).
“The mobile robot market is undergoing massive growth and transformation as autonomous platforms such as autonomous mobile robots (AMRs) get widely adopted indoors and outdoors. Collaborating with NVIDIA on the Jetson platform integration has helped us advance the use of Xsens MTi sensors in mobile robotics and edge AI,” said Meindert Zeeuw, Director of the “Automation & Mobility” Line of Business at Movella. “The seamless integration of Xsens MTi’s precise and real-time data with NVIDIA Jetson’s accelerated computing capabilities will help innovators further in developing systems that can navigate, perceive, and interact with their environments with even more accuracy and agility.”
This integration highlights the momentum of the industrial inertial sensor market, particularly in logistics (autonomous robots, autonomous vehicles) and sea-based (ROV/AUV) applications. This segment has a projected 16% CAGR expected from 2021 to 2027, reaching an estimated value of USD 1.1 billion. Movella’s work underscores the industry’s rapid innovation and adoption of industrial inertial sensors, positioning the company to drive transformative advancements in intelligent automation within industrial applications.
About Movella
Movella is a leading full-stack provider of sensors, software, and analytics that enable the digitization of movement. Movella serves the automation & mobility, entertainment and health & sports markets. Movella's innovations enable customers to capitalize on the value of movement by transforming data into meaningful and actionable insights. Partnering with leading global brands such as ABB Marine, Hewlett Packard, Kongsberg, Clearpath Robotics, Toyota, Siemens, Electronic Arts, EPIC Games, 20th Century Studios, Netflix and more than 500 sports organizations, Movella is creating extraordinary outcomes that move humanity forward. To learn more, please visit www.movella.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716567003/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom